PD23-15: Safety of rucaparib vs docetaxel or second-generation androgen receptor pathway inhibitor therapy for patients with metastatic castration-resistant prostate cancer and a BRCA mutation in TRITON3

PD23-15: Safety of rucaparib vs docetaxel or second-generation androgen receptor pathway inhibitor therapy for patients with metastatic castration-resistant prostate cancer and a BRCA mutation in TRITON3

Sunday, May 17, 2026 5:22 PM to 5:30 PM · 8 min. (America/New_York)
206
Abstract

Speakers

AB
Alan Bryce

Log in

See all the content and easy-to-use features by logging in or registering!